Rapport Therapeutics (RAPP) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Rapport Therapeutics used $87.47M of cash in operating activities and spent $616.00K on capital expenditures. That left free cash flow of −$88.09M. It repurchased $1.00K of its own shares.

Rapport Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Rapport Therapeutics, Inc. (RAPP) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Operating Activities
Net Income	-111.48	-78.31	-34.79	-11.62
Depreciation & Amortization	1.02	0.84	0.11	0.02
Stock Based Compensation	18.86	10.24	3.53	0.61
Change in Working Capital	3.50	-2.42	2.65	1.62
Change in Accounts Payable	2.22	-0.35	0.86	1.58
Change in Other Working Capital	1.29	-2.44	-3.58	0.05
Other Operating Activities	0.64	4.82	1.32	0.38
Net Cash from Operating Activities	-87.47	-64.83	-27.18	-3.54
Investing Activities
Capital Expenditures	-0.62	-2.41	-1.64	-0.31
Purchases of Investments	-354.78	-377.53	-77.22	0.00
Sales/Maturities of Investments	167.93	209.80	0.00	-5.45
Other Investing Activities	0.00	3.21	0.00	-5.00
Net Cash from Investing Activities	-187.47	-170.14	-78.86	-5.76
Financing Activities
Debt Repayment	0.00	0.00	0.00	7.90
Common Stock Issued	270.79	157.71	0.05	0.03
Common Stock Repurchased	0.00	0.00	0.00	0.00
Other Financing Activities	0.00	63.92	-0.13	-0.11
Net Cash from Financing Activities	270.79	221.63	145.14	43.29
Summary
Net Change in Cash	-4.16	-13.34	39.10	33.99
Cash at Beginning of Period	56.91	70.25	31.16	0.00
Cash at End of Period	52.75	56.91	70.25	31.16
Free Cash Flow	-88.09	-67.23	-28.82	-3.85

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Rapport Therapeutics Cash Flow

What is Rapport Therapeutics's free cash flow?

Rapport Therapeutics had negative free cash flow of $88.09M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$87.47M minus $616.00K of capital expenditures.

How much does Rapport Therapeutics spend on capital expenditures?

Rapport Therapeutics spent $616.00K on capital expenditures in fiscal 2025, compared with $2.40M a year earlier.

Does Rapport Therapeutics pay dividends or buy back shares?

Yes. In fiscal 2025 Rapport Therapeutics returned $1.00K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition